MPLT: Mixed Results

MapLight Therapeutics Inc. (NASDAQ: MPLT ) reported mixed topline results from its Phase 2 IRIS study of ML-004 in patients with autism spectrum disorder .

The trial missed the trial’s primary endpoint while demonstrating clinically meaningful improvements in irritability among a subgroup of adolescents. • MapLight Therapeutics stock is among today’s top performers.

What’s fueling MPLT momentum? The findings, shared on Monday, could support further development of the drug in a more targeted patient population, reinforcing analysts’ views that ML-004 may still hold significant commercial potential .

Primary Endpoint Missed In Broad Autism Population The IRIS study enrolled 161 participants, including 102 adolescents and 59 adults, and was designed as an exploratory Phase 2 trial to assess multiple clinical outcomes and identify the most suitable development strategy for ML-004.

The study failed to achieve its primary endpoint, which measured changes from baseline through week 12 in caregiver-reported social communication scores using the Autism Behavioral Inventory Social Communication Domain .

MapLight noted that social communication remains an area without approved pharmacological treatments and that validated measures capable of detecting treatment-related changes continue to be actively studied.

Read Also: MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst Adolescent Subgroup Demonstrates Strong Irritability Benefit Despite the primary endpoint miss, ML-004 produced encouraging results in a prespecified subgroup of adolescents ages 12 to 17 who entered the study with moderate or greater irritability .

Among these participants, ML-004 generated clinically meaningful improvements versus placebo on the Aberrant Behavior Checklist-Irritability subscale, with a least squares mean difference of negative 9.58 and an effect size of 1.33.

The company also reported favorable results on the Clinician Global Impression-Improvement irritability domain, where adolescents receiving ML-004 showed greater improvement than those receiving a placebo.

Treatment benefits appeared strongest among adolescents with the highest baseline irritability levels.

In the broader population of participants with elevated irritability scores, ML-004 achieved an effect size of 0.64 on a key secondary endpoint, although the result did not reach nominal statistical significance .

Safety Profile Remains Favorable MapLight said ML-004 was generally well tolerated, with all treatment-emergent adverse events classified as mild to moderate.

No serious or severe adverse events occurred among participants receiving ML-004.

By comparison, placebo-treated participants experienced two severe treatment-emergent adverse events and one serious adverse event.

Investigators observed no extrapyramidal adverse events in patients receiving ML-004, while average weight gain during the study was lower in the treatment arm than in the placebo group .

MPLT Stock Price Activity : MapLight Therapeutics shares were up 5.52% at $30.41 at the time of publication on Monday, according to Benzinga Pro data .

Image via Shutterstock/ tomertu Read Also: India Races To Seal US Trade Deal Before Key Tariff Deadline, Eyes Preferential Rates: 'The Faster, The Better'